Esteve to market Eisai's Fycompa in Spain

4 February 2016

Japanese drug major Eisai (TYO: 4523) has entered into a new agreement with Spain’s Esteve to co-promote Fycompa (perampanel) in Spain from February 2016. No financial details of the accord were disclosed.

Eisai and Esteve will launch the new indication for the adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in adults and adolescents (≥12 years) with idiopathic generalized epilepsy (IGE) in Spain in early 2016. Perampanel is also indicated in Spain for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

"We are pleased to further strengthen our relationship with Esteve under this new agreement to co-promote perampanel. This collaboration will ensure that we maximize access to our products for people with epilepsy (per indication) in Spain," commented Gary Hendler, president and chief executive of Eisai EMEA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK